GlassScriptPhysician profile
Melissa Dawn Fox
NPI 1326266776
$600.55
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $178 · 2021: $116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $158.42 | 2019-2021 | |
| Glaxosmithkline, LLC. | $131.03 | 2019-2021 | |
| Adlon Therapeutics L.P. | $101.99 | 2019-2021 | |
| Tris Pharma INC | $78.70 | 2019-2021 | |
| Kaleo, INC. | $30.74 | 2020-2021 | |
| Neos Therapeutics, LP | $29.58 | 2020 | |
| Genentech USA, INC. | $26.13 | 2019 | |
| Cranial Technologies, INC | $15.07 | 2021 | |
| Sanofi Pasteur INC. | $14.66 | 2019 | |
| Merck Sharp & Dohme LLC | $14.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.